Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S38.007)
To report the interim efficacy and safety (data cutoff: Jun 14, 2024) of ravulizumab in AQP4-Ab+ NMOSD.
Authors
- Jacqueline Palace (ORCID: https://orcid.org/0000-0002-2934-9383)
- Kerstin R. Allen (ORCID: https://orcid.org/0009-0004-9286-6158)
- Jerome De Seze (ORCID: https://orcid.org/0000-0002-7197-7578)
- Jeffrey L. Bennett (ORCID: https://orcid.org/0000-0002-3346-1394)
- Achim Berthele (ORCID: https://orcid.org/0000-0001-9650-6222)
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Ichiro Nakashima (ORCID: https://orcid.org/0000-0002-2612-8948)
- Carlo Pozzilli (ORCID: https://orcid.org/0000-0002-6360-4798)
- Michael Harry Barnett (ORCID: https://orcid.org/0000-0002-2156-8864)
- Sean Joseph Pittock (ORCID: https://orcid.org/0000-0002-6140-5584)
- Michaël Levy (ORCID: https://orcid.org/0000-0003-2766-5777)
- Ho Jin Kim (ORCID: https://orcid.org/0000-0002-8672-8419)
- Celia Oreja Guevara
- Becky Jo Parks (ORCID: https://orcid.org/0009-0006-0881-975X)
Institutions
- Universidad Complutense de Madrid (ES)
- The University of Sydney (AU)
- Harvard University (US)
- Max Delbrück Center (DE)
- University of Colorado System (US)
- WinnMed (US)
- John Radcliffe Hospital (GB)
- Hospital Clínico San Carlos (ES)
- Massachusetts General Hospital (US)
- AstraZeneca (Brazil) (BR)
- Alexion Pharma (Switzerland) (CH)
- Technical University of Munich (DE)
- Université de Strasbourg (FR)
- Charité - Universitätsmedizin Berlin (DE)
- Tohoku Medical and Pharmaceutical University (JP)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208711
- Citations
- 1
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39